Literature DB >> 9578047

Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics.

R C Scott1, F M Besag, S G Boyd, D Berry, B G Neville.   

Abstract

PURPOSE: To determine whether buccal/sublingual administration of midazolam (MDL) would lead to detectable venous concentrations and EEG changes in 10 healthy volunteers.
METHODS: The study consisted of an open-label and a double-blind phases. Subjects held 10 mg MDL in 2 ml peppermint-flavored fluid or peppermint-flavored placebo in their mouth for 5 min and then spat it out. Cardiorespiratory and EEG monitoring was performed in all subjects.
RESULTS: Venous MDL concentrations measured on 10 occasions from 5 to 600 min after administration showed a rapid increase for the first 20-30 min. However, changes in the 8- to 30-Hz frequencies identified by spectral analysis of the EEG showed changes in < or = 5-10 min in test but not in control subjects--more rapid than were expected from the venous absorption data. There were no significant adverse effects.
CONCLUSIONS: Our data provide direct evidence of the speed of cerebral effect of a drug. Our results suggest that the buccal/sublingual route of administration should be tested in emergency treatment of seizures as an alternative to the rectal route, over which it has clear practical advantages.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578047     DOI: 10.1111/j.1528-1157.1998.tb01375.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  15 in total

Review 1.  Typical absence seizures and their treatment.

Authors:  C P Panayiotopoulos
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Intranasal midazolam for treating febrile seizures in children. Caution is advised in interpreting trial conclusions.

Authors:  T Johnson
Journal:  BMJ       Date:  2001-01-13

Review 3.  Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures.

Authors:  Heather Ravvin McKee; Bassel Abou-Khalil
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 4.  Oromucosal midazolam: a review of its use in pediatric patients with prolonged acute convulsive seizures.

Authors:  Karly P Garnock-Jones
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

Review 5.  Alternative delivery systems for agents to treat acute agitation: progress to date.

Authors:  Kimberly Nordstrom; Michael H Allen
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 6.  Cerebral malaria: optimising management.

Authors:  Neema Mturi; Crispin O Musumba; Betty M Wamola; Bernhards R Ogutu; Charles R J C Newton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Inappropriate emergency management of status epilepticus in children contributes to need for intensive care.

Authors:  R F M Chin; L Verhulst; B G R Neville; M J Peters; R C Scott
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 8.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective.

Authors:  Marco Mula
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

10.  Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability.

Authors:  Mark Anderson
Journal:  Patient Prefer Adherence       Date:  2013-01-10       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.